# US 10,441,593 B2 · Treatment of pain associated with dislocation of endometrium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,593 B2
- Document ID: US10441593B2
- Status: Granted
- Kind: B2
- Application number: 13/976,895
- Filed: 2011-12-23
- Published: 2013-10-24
- Granted: 2019-10-15
- Earliest claimed: 2010-12-30
- Assignees: PregLem SA
- Applicants: Ernest Loumaye; Elke Bestel; Ian Osterloh
- Inventors: Ernest Loumaye; Elke Bestel; Ian Osterloh
- Web page: https://patentgrep.com/patent/US10441593B2

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 5/24: of the sex hormones
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to gynecological diseases and in particular to a method for reducing pain associated with dislocation of basal endometrium.

## Claims

### Claim 1

A method for the treatment of pain associated with dislocation of the endometriumin a patient, comprising administering ulipristal or a metabolite thereof selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 to the patient in need thereof,
wherein said ulipristal, or said metabolite thereof, is administered at a daily dosage of about 5 to 12 mg,
wherein the dislocation of the endometrium results in adenomyosis or endometriosis, and
wherein the pain is chronic pelvic pain, pain with intercourse, low back pain, painful bowel movements, painful urination during menstruation, or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method comprises administering a tablet comprising the ulipristal or the metabolite thereof to the patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the daily dosage of ulipristal, or the metabolite thereof, is about 5 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the daily dosage of the ulipristal, or the metabolite thereof, is about 10 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ulipristal or the metabolite thereof is administered for a period of 1 to up to 120 days.

### Claim 6 (depends on 1)

The method of claim 1, wherein the painful bowel movements is during menstruation.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ulipristal or the metabolite thereof is administered for about 13 weeks.